Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject

Neuropathology

Volumn 25, Issue 4, 2005, Pages 304-314

  Parkkinen, Laura ^a   Pirttilä, Tuula ^a,b   Tervahauta, Markku ^c   Alafuzoff, Irina ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Leppävirta Health Care Center   (Finland)

Author keywords

synuclein; amyloid; Gliosis; Inclusion; Neurologically unimpaired

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 GLYCOPROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AT8; MONOCLONAL ANTIBODY M0872; NCL ASYN MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY Z0334; POLYCLONAL ANTIBODY Z0458; PROTEIN P62 LCK LIGAND; SYNUCLEIN 1 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CASE REPORT; CELL DISRUPTION; CELL FUNCTION; CELL INCLUSION; CELL VIABILITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; FEMALE; GLIA; GLIOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEWY BODY; NERVE CELL; NEUROLOGICALLY UNIMPAIRED SUBJECT; NEUROPATHOLOGY; NICK END LABELING; PATIENT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PUTAMEN; SYNUCLEINOPATHY; VASCULAR DISEASE; BRAIN; COMPARATIVE STUDY; DIFFUSE LEWY BODY DISEASE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; APOPTOSIS; BRAIN; HUMANS; IMMUNOHISTOCHEMISTRY; LEWY BODY DISEASE; NEUROGLIA; NEURONS;

EID: 33644830518     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2005.00644.x     Document Type: Article

References (49)

1. Polymeropoulos MH Lavedan C Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997 276 : 2045 2047.
2. Kruger R Kuhn W Muller T et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998 18 : 106 108.
3. Spillantini MG Schmidt ML Lee VM Trojanowski JQ Jakes R Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997 388 : 839 840.
4. Singleton AB Farrer M Jonhson J et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003 302 : 841.
5. Masliah E Rockenstein E Veinbergs I et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000 287 : 1265 1269.
6. Feany MB Bender WW. A Drosophila model of Parkinson's disease. Nature 2000 404 : 394 398.
7. Betarbet R Sherer TB MacKenzie G Garcia-Osuna M Panov AV Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000 3 : 1301 1306.
8. Meredith GE Halliday GM Totterdell S. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat Disord 2004 10 : 191 202.
9. Saha AR Ninkina NN Hanger DP Anderton BH Davies AM Buchman VL. Induction of neuronal death by alpha-synuclein. Eur J Neurosci 2000 12 : 3073 3077.
10. Xu J Kao SY Lee FJ Song W Jin LW Yankner BA. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002 8 : 600 606.
11. Parkkinen L Soininen H Laakso M Alafuzoff I. Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 2001 27 : 314 325.
12. Lipkin LE. Cytoplasmic inclusions in ganglion cells associated with parkinsonian states: a neurocellular change studied in 53 cases and 206 controls. Am J Pathol 1959 35 : 1117 1133.
13. Woodard JS. Concentric hyaline inclusion body formation in mental disease analysis of twenty-seven cases. J Neuropathol Exp Neurol 1962 21 : 442 449.
14. Forno LS. Lewy bodies and aging: relation to Alzheimer's and Parkinson's diseases. Neurodegeneration 1993 2 : 19 24.
15. Gibb WR Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988 51 : 745 752.
16. Perry RH Irving D Tomlinson BE. Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci 1990 100 : 223 233.
17. Lindboe CF Hansen HB. The frequency of Lewy bodies in a consecutive autopsy series. Clin Neuropathol 1998 17 : 204 209.
18. Ince PG McArthur FK Bjertness E Torvik A Candy JM Edwardson JA. Neuropathological diagnoses in elderly patients in Oslo: Alzheimer's disease, Lewy body disease, vascular lesions. Dementia 1995 6 : 162 168.
19. Esiri M Matthews F Brayne C Ince PG. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001 357 : 169 175.
20. Hurtig HI Trojanowski JQ Galvin J et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000 54 : 1916 1921.
21. Mattila PM Rinne JO Helenius H Dickson DW Roytta M. Alpha-synuclein- immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl) 2000 100 : 285 290.
22. Harding AJ Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 2001 102 : 355 363.
23. Apaydin H Ahlskog JE Parisi JE Boeve BF Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002 59 : 102 112.
24. Kovari E Gold G Herrmann FR et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol (Berl) 2003 106 : 83 88.
25. Parkkinen L Kauppinen T Pirttila T et al. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005 57 : 82 91.
26. Braak H Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991 82 : 239 259.
27. Alafuzoff I Helisalmi S Mannermaa A Rickkinen PSr Soininen H. Beta-amyloid load is not influenced by the severity of cardiovascular disease in aged and demented patients. Stroke 1999 30 : 613 618.
28. McKeith IG Galasko D Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996 47 : 1113 1124.
29. Braak H Del Tredici K Rub U de Vos RA Jansen Steur EN Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 24 : 197 211.
30. Terry RD. Do neuronal inclusions kill the cell? J Neural Transm Suppl 2000 59 : 91 93.
31. Kremer HP Bots GT. Lewy bodies in the lateral hypothalamus: do they imply neuronal loss? Mov Disord 1993 8 : 315 320.
32. Gomez-Isla T Growdon WB McNamara M et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999 53 : 2003 2009.
33. Auluck PK Chan HY Trojanowski JQ Lee VM Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002 295 : 865 868.
34. Lo Bianco C Ridet JL Schneider BL Deglon N Aebischer P. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 2002 99 : 10813 10818.
35. Hatanpaa K Brady DR Stoll J Rapoport SI Chandrasekaran K. Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1996 40 : 411 420.
36. Morsch R Simon W Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 1999 58 : 188 197.
37. Gertz HJ Siegers A Kuchinke J. Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease. Brain Res 1994 637 : 339 341.
38. Tompkins MM Hill WD. Contribution of somal Lewy bodies to neuronal death. Brain Res 1997 775 : 24 29.
39. Kitada T Asakawa S Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998 392 : 605 608.
40. van Duinen SG Lammers GJ Maat-Schieman ML Roos RA. Numerous and widespread alpha-synuclein-negative Lewy bodies in an asymptomatic patient. Acta Neuropathol (Berl) 1999 97 : 533 539.
41. Colosimo C Hughes AJ Kilford L Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003 74 : 852 856.
42. Tanaka M Kim YM Lee G Junn E Iwatsubu T Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004 279 : 4625 4631.
43. Lansbury PT Jr. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A 1999 96 : 3342 3344.
44. Caughey B Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003 26 : 267 298.
45. Olanow CW Perl DP DeMartino GN McNaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004 3 : 496 503.
46. Katsuse O Iseki E Marui W Kosaka K. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci 2003 211 : 29 35.
47. Duda JE. Pathology and neurotransmitter abnormalities of dementia with lewy bodies. Dement Geriatr Cogn Disord 2004 17 : 3 14.
48. MacKenzie IR. Activated microglia in dementia with Lewy bodies. Neurology 2000 55 : 132 134.
49. Kingsbury AE Mardsen CD Foster OJ. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov Disord 1998 13 : 877 884.